D-dimer elevation after first alemtuzumab administration in a multiple sclerosis patient: case report

Acta Neurol Belg. 2023 Feb;123(1):275-277. doi: 10.1007/s13760-021-01822-y. Epub 2021 Oct 24.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Alemtuzumab / adverse effects
  • Fibrin Fibrinogen Degradation Products
  • Humans
  • Immunologic Factors
  • Multiple Sclerosis* / drug therapy
  • Multiple Sclerosis, Relapsing-Remitting* / drug therapy

Substances

  • Alemtuzumab
  • fibrin fragment D
  • Fibrin Fibrinogen Degradation Products
  • Immunologic Factors